Increasing work-place healthiness with the probiotic Lactobacillus reuteri: A randomised, double-blind placebo-controlled study by Tubelius, Py et al.
BioMed  Central
Page 1 of 5
(page number not for citation purposes)
Environmental Health: A Global 
Access Science Source
Open Access Research
Increasing work-place healthiness with the probiotic Lactobacillus 
reuteri: A randomised, double-blind placebo-controlled study
Py Tubelius1, Vlaicu Stan1 and Anders Zachrisson*2
Address: 1Tetra Pak Occupational Health and Safety AB, Ruben Rausings Gata, 221 86 Lund, Sweden and 2BioGaia AB, St Lars Väg 42A, 220 09, 
Lund, Sweden
Email: Py Tubelius - py.tubelius@tetrapak.com; Vlaicu Stan - Vlaicu.Stan@tetrapak.com; Anders Zachrisson* - az@biogaia.se
* Corresponding author    
Abstract
Background: Short term illnesses, usually caused by respiratory or gastrointestinal diseases are
disruptive to productivity and there is relatively little focus on preventative measures. This study
examined the effect of the probiotic Lactobacillus reuteri protectis (ATCC55730) on its ability to
improve work-place healthiness by reducing short term sick-leave caused by respiratory or
gastrointestinal infections.
Methods: 262 employees at TetraPak in Sweden (day-workers and three-shift-workers) that were
healthy at study start were randomised in a double-blind fashion to receive either a daily dose of
108  Colony Forming Units of L. reuteri or placebo for 80 days. The study products were
administered with a drinking straw. 181 subjects complied with the study protocol, 94 were
randomised to receive L. reuteri and 87 received placebo.
Results: In the placebo group 26.4% reported sick-leave for the defined causes during the study
as compared with 10.6% in the L. reuteri group (p < 0.01). The frequency of sick-days was 0.9% in
the placebo group and 0.4% in the L. reuteri group (p < 0.01). Among the 53 shift-workers, 33% in
the placebo group reported sick during the study period as compared with none in the L. reuteri
group(p < 0.005).
Introduction
The general well-being in work-places is receiving
increased attention in Sweden. Not only is the well-being
and healthiness important to the individual himself, but
also important to fellow co-workers, family members and
last but not least to the success of the company. During
the last few decades increased focus have been on how to
increase well-being by offering company-sponsored
health care, memberships in fitness centres and similar
programs aiming to prevent and cure disease and to
increase physical activity and awareness on health issues.
Comparatively little attention has been on the diet and
how a daily healthy diet impacts on general health with
the exception of anti-obesity initiatives.
The cost due to short term sick-leave is in Sweden alone
estimated to more than 2.2 billion € [1] and a majority
(50–60%) of the episodes are caused by diseases in the
respiratory tract (common cold) and gastrointestinal
infections [2].
Of special interest is the well-being among shift-workers
as this group is known to be at significantly higher risk to
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attract short-term illnesses such as the common cold and
gastroenteritis [3].
Probiotics, i.e. naturally occurring bacteria with health
benefits are gaining wider acceptance. These bacteria,
commonly from the Lactobacillus family have been dem-
onstrated to have numerous potentially important bene-
fits in terms of gut health and immunity [4], but very few
studies address how these effects translate into health ben-
efits in normal populations.
Recently, it was demonstrated in a double blind study [5]
that gastrointestinal illnesses and febrile episodes could
be significantly reduced in babies attending day-care cent-
ers. This was achieved by adding the probiotic Lactobacillus
reuteri  t o  i n f a n t  f o r m u l a  d u r i n g  a  1 2  w e e k  l o n g  s t u d y
period.
This study aimed to evaluate if similar effects could be
achieved in adults and if the addition of the probiotic L.
reuteri as a daily dietary supplement can improve work-
place healthiness.
Materials and methods
Healthy volunteers were recruited among employees at
Tetra Pak in Sweden. The criteria for participation were
that they should be symptom-free at Day 0, between 18–
65 years of age, willing to comply with the protocol and
that signed informed consent was obtained. The study
protocol was approved by the ethical committee at Lund
University Hospital.
The overall study period was set to 80 days. The subjects
were allowed to miss study treatment occasionally, but
not for more than a total of 7 days.
The volunteers were randomised in a double-blind fash-
ion to take a daily probiotic drinking straw together with
at least 100 ml liquid. Each straw delivered 108 Colony
Forming Units (CFU) of L. reuteri protectis, ATCC55730
or placebo.
During the study period the volunteers were asked to
report in a diary format any illness symptoms related to
the respiratory tract and/or the gastrointestinal tract
resulting in sick-leave, and if so, the duration of the sick-
leave. They were also asked to report if they had taken the
study product as instructed or, if applicable, how many
days they missed taking the study product. The diaries
were distributed on Day 0 together with the study product
and were collected after finalisation of the study period.
Subjects were randomly assigned to L Reuteri (50%), Pla-
cebo (50%) in blocks of 4 by a person handing out a
sequentially numbered package, containing either L Reu-
teri or Placebo, together with a diary marked with the
same randomisation number. The packages containing
either L Reuteri or Placebo were identical in appearance.
The randomisation list was generated bythe data manage-
ment company and used for sorting and numbering the
packages by another person. A list in a sealed envelope
was kept by the sponsor. Randomisation envelopes were
also generated bythe data management company, and
kept for safety by the sponsor. The list of randomisation
was kept confidential by the statisticians until all results
had been generated and sealed.
Results
After ethical committee approval had been granted,
informed consent was obtained from 262 employees who
started treatment. 132 were randomised to receive L. reu-
teri and 130 randomised to placebo. 38 subjects in the L.
reuteri group and 43 in the placebo group failed to comply
with the full protocol requirements and were withdrawn
from further analysis. In all cases the reason for non-com-
pliance was that they failed to take the study treatment in
accordance with the protocol.
The demographic data for the remaining 181 subjects are
given in table 1. There were no statistically significant
demographic differences between the two groups.
The data for symptoms and sick-leave are given in table 2
and figure 1. In the placebo group 23 of 87 subjects
reported sick-leave during the study. The corresponding
number in the L. reuteri group was 10 of 94 (p < 0.01).
Consequently, the percentage of sick-days of working days
fell from 0.9% in the placebo group to 0.4% in the L. reu-
teri group. This difference was also statistically significant
(p < 0.01). However, the median length of sick-leave
among the subjects who reported any sick-leave was equal
in the two groups, 3 days.
Among the 53 shift-workers in the study, 9 of 27 (33%) in
the placebo group reported sick-leave as compared with
none of the 26 (0%) in the L. reuteri group (p < 0.005,
Fisher's exact) (figure 1).
There were no adverse events reported during the study.
Table 1: Demographic data
L. reuteri Group 
n = 94
Placebo Group 
n = 87
Mean age (years) 44 44
Male / Female (%) 65/35 71/29
Shift work (%) 28 31Environmental Health: A Global Access Science Source 2005, 4:25 http://www.ehjournal.net/content/4/1/25
Page 3 of 5
(page number not for citation purposes)
Discussion
The proportion of subjects that were withdrawn for rea-
sons of non-compliance was fairly high, 31%. This can
most probably be explained by the study design itself in
combination with the fairly long study duration. When
the study was designed it was decided that the study staff
should meet the study subjects as little as possible in order
to minimise any placebo effect as it was assumed that fre-
quent contacts could increase the individual subject's
awareness of health issues beyond the normal behaviour.
The outcome of the study demonstrates that daily intake
of L. reuteri can reduce the proportion of subjects report-
ing sick from gastrointestinal or respiratory tract diseases
by 60%. The effect was highly statistically significant and
similar to the findings by Weizman et al [5], where small
children in day-care centres had a 70% lower frequency of
absence when given L. reuteri as compared with placebo.
As demonstrated elsewhere [6-8], L. reuteri is efficient
both in preventing and treating acute diarrhoea and gas-
troenteritis in young children. In a study on healthy adults
it was shown that L. reuteri was able to stimulate the
immune system by recruiting CD4+-cells [9]. Such stimu-
lation by L. reuteri has been observed in animal models
and is associated with an improved response to pathogen
infection [10]. Although the exact mechanism of action
cannot be defined from our study it is likely that such an
immune-stimulation lies behind the reduced morbidity
in the subjects taking L. reuteri. This stimulation may also
explain why the beneficial effect of L. reuteri in our study
was specifically apparent among shift-workers. This sub-
set consisted of 31% of the total study groups and there-
fore some caution is warranted when interpreting this
result. Nevertheless, shift-workers are known to be at risk
for having a weaker immuno-defence as compared to
those working day-time shifts only [3]. Consequently it
can be argued that shift-workers would benefit relatively
more by the immuno-stimulating effect of L. reuteri.
In conclusion, the present study demonstrates that L. reu-
teri is effective to promote work-place healthiness. In the
studied population sick-days caused by respiratory or gas-
trointestinal diseases could be reduced by 55% by the use
of L. reuteri group as compared with the placebo group.
Translated to the total Swedish work-force, this translates
to a total of 4.3 million working days of improved pro-
ductivity per year (3.9 million employed, 220 working
days per year and 0,5% "saved" days). Our results indicate
that the effect on shift-work productivity could probably
be even more profound but this issue should be addressed
in further studies.
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Proportion (%) of subjects reporting sick during the study Figure 1
Proportion (%) of subjects reporting sick during the study. ■  = Placebo;   = L. reuteri.
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